TELA Bio director granted stock and options

TELA Bio director William J. Plovanic received new equity awards as part of his compensation.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

TELA Bio director William J. Plovanic received new equity awards as part of his compensation. He was granted 11,675 shares of common stock and a stock option for 17,335 shares at an exercise price of $0.935 per share.

The stock units and the option both vest on the earlier of June 9, 2027, the next annual meeting of stockholders, or a Change in Control under TELA Bio’s Amended and Restated 2019 Equity Incentive Plan, in each case subject to his continued service. Following the grant, he directly owns 23,600 common shares and holds the new option for 17,335 underlying shares.

Insider Trade Summary

Grant/Award: 29,010 shares

Grant/Award 2 txns

Insider Plovanic William J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	17,335	$0.00	$0.00
Grant/Award	Common Stock	11,675	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 17,335 contracts (Direct); Common Stock — 23,600 shares (Direct)

Footnotes (2)

F1. These restricted stock units vest on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
F2. The option vests on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Restricted stock units granted: 11,675 shares Stock options granted: 17,335 options Option exercise price: $0.935 per share +2 more

5 metrics

Restricted stock units granted 11,675 shares Common Stock award to director on June 9, 2026

Stock options granted 17,335 options Right to buy Common Stock granted June 9, 2026

Option exercise price $0.935 per share Stock Option (Right to Buy) underlying Common Stock

Shares held after grant 23,600 shares Total TELA Bio common stock directly owned after award

Option expiration June 9, 2036 Expiration date of granted stock option

Key Terms

restricted stock units, Change in Control, Amended and Restated 2019 Equity Incentive Plan, Stock Option (Right to Buy)

4 terms

restricted stock units financial

"These restricted stock units vest on the earlier of (a) June 9, 2027..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Change in Control financial

"..., or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended..."

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Amended and Restated 2019 Equity Incentive Plan financial

"Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan)..."

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TELA (TELA) director William J. Plovanic receive in this Form 4?

William J. Plovanic received equity compensation consisting of 11,675 shares of TELA Bio common stock and a stock option covering 17,335 shares. These awards are part of his director compensation and were not open-market purchases or sales.

At what price can the new TELA (TELA) stock options be exercised?

The newly granted stock option to director William J. Plovanic has an exercise price of $0.935 per share. This means he can buy up to 17,335 TELA Bio shares at that fixed price once the options vest, subject to the vesting conditions.

When do William J. Plovanic’s new TELA (TELA) equity awards vest?

Both the restricted stock units and the stock option vest on the earlier of June 9, 2027, the next annual stockholders’ meeting, or a Change in Control. Vesting in each case requires William J. Plovanic to continue serving through the applicable vesting date.

How many TELA (TELA) shares does William J. Plovanic own after this grant?

After the equity grant, William J. Plovanic directly owns 23,600 shares of TELA Bio common stock. In addition, he holds a stock option for 17,335 underlying common shares that can be exercised at $0.935 per share once vested.

Is this TELA (TELA) Form 4 a stock purchase or sale by the director?

This Form 4 reflects compensation-related acquisitions, not open-market trades. William J. Plovanic received restricted stock units and a stock option grant at no cash cost, so there are no reported purchases or sales in the public market in this filing.

What triggers early vesting of TELA (TELA) director William J. Plovanic’s awards?

The awards vest early upon the next annual meeting of stockholders or a Change in Control, whichever occurs first. In all cases, vesting is conditioned on William J. Plovanic’s continued service to TELA Bio through the relevant vesting date specified in the plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/11/2026 - 06:09 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plovanic William J.

(Last)

(First)

(Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MAVERN

PENNSYLVANIA

19355

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/09/2026		A		11,675⁽¹⁾	A	$0	23,600	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.935	06/09/2026		A		17,335		⁽²⁾	06/09/2036	Common Stock	17,335	$0	17,335	D

Explanation of Responses:

1. These restricted stock units vest on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.

2. The option vests on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Megan Smeykal, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR